Formycon and Bioeq Launch FYB201 in Canada and Switzerland

Formycon AG and Bioeq AG announced the commercial release of FYB201, a biosimilar to Lucentis®, in Canada and Switzerland, expanding its global presence to 17 countries. Marketed as RanoptoTM in Canada and Ranivisio® in Switzerland, this launch brings a cost-effective solution for serious retinal diseases to more patients. Teva, the commercialization partner, has begun distributing the product following approvals by Health Canada and Swissmedic.

FYB201 offers an important treatment option for age-related macular degeneration (AMD) and other retinal conditions. Increasing prevalence of these diseases poses a significant health concern, particularly in aging populations. FYB201, inhibiting vascular endothelial growth factor (VEGF), addresses the excessive blood vessel growth associated with the wet form of AMD, a leading cause of severe visual impairment in developed countries. Estimates indicate around 67 million people in Europe and 2.5 million in Canada are affected by AMD, numbers expected to rise.